Mumbai, November 28, 2017: Pharma major Dr Reddy’s Laboratories Ltd said that it has launched Clofarabine injection, a therapeutic and generic equivalent of Clolar injection of Genzyme Corporation, in the US market, approved by the USFDA.
The Clolar brand and generic had the US sales of approximately USD53 million for the most recent 12 months ended September 2017 as per IMS Health,company said in afiling with BSE. The drug is indicated for treating a particular type of cancer, among other prescribed use.
Dr Reddy Laboraties Clofarabine injection is avaliable in single-dose, 20 mL fints vials contaning 20 mg of Clofarabine in 20 mL of solution.(1mg/mL).
United News Of India
